Designing Site Feasibility Questionnaires that Drive Successful Clinical Trial Site Selection

A well-designed site feasibility questionnaire (SFQ) is essential for evaluating and selecting the right sites for clinical trials. The SFQ allows sponsors and CROs to collect critical operational, regulatory, and clinical information from potential sites to assess their suitability for a given study. This guide explains how to create effective, actionable feasibility forms that enable informed decisions during trial planning.

Purpose of a Site Feasibility Questionnaire

The site feasibility questionnaire serves as a foundational tool for:

• Evaluating a site’s ability to comply with study protocols
• Assessing site infrastructure, patient pool, and staff availability
• Identifying regulatory, logistical, or operational challenges
• Facilitating early communication between sponsor and investigator

Core Components of a Site Feasibility Questionnaire

1. Site and Investigator Information

• Site name, address, and contact information
• Principal Investigator (PI) qualifications and experience
• GCP training certificates and prior trial participation

2. Study Experience and Therapeutic Expertise

• Experience with the specific indication or similar trials
• Number of studies conducted in the last 2 years
• Regulatory inspection history and outcomes

3. Infrastructure and Equipment Availability

• Availability of pharmacy, laboratory, and diagnostic facilities
• Access to equipment required by the protocol (e.g., ECG, centrifuge)
• EDC and internet capabilities for remote data entry

4. Patient Population and Recruitment Capacity

• Estimated number of eligible patients per month
• Access to target patient population through internal or referral networks
• Recruitment strategies used in past studies

5. Operational Readiness

• Site’s SOPs for trial conduct
• Availability of dedicated study coordinators
• Turnaround time for ethics committee (EC) and regulatory submissions

Best Practices in Questionnaire Design

1. Use Standardized Templates: Leverage validated templates from Pharma SOP templates or sponsor-provided forms to ensure uniformity.
2. Design Study-Specific Sections: Include questions aligned with the protocol requirements such as number of blood draws, patient diary handling, or imaging capabilities.
3. Include Objective and Subjective Responses: Use checkboxes, drop-downs, and rating scales, but also allow free-text for investigator comments.
4. Keep It Concise: Limit the form to critical fields, ideally within 4–6 pages, to encourage completion.
5. Digital Distribution: Utilize tools like REDCap, SurveyMonkey, or CTMS-integrated forms to capture responses electronically.

How to Analyze Feasibility Responses

Once responses are collected, sponsors and CROs should evaluate them against pre-defined feasibility criteria:

• Protocol-specific capabilities
• Patient recruitment projections
• Site compliance history and audit results
• Geographic diversity and regulatory ease

Sites can be scored or ranked using feasibility algorithms embedded in CTMS or Excel-based scoring sheets.

Common Pitfalls to Avoid

• Asking too many generic questions that do not impact study execution
• Failing to update the questionnaire for each study’s protocol
• Not validating the accuracy of provided information through monitoring
• Over-reliance on past performance without evaluating current capacity

Example: Sample Questions for Oncology Trial Feasibility

• How many lung cancer patients did you enroll in studies over the last 12 months?
• Do you have access to on-site PET-CT imaging?
• Is there an in-house pharmacy capable of handling cytotoxic agents?
• Do you have GCP-certified backup investigators?
• What is your average EC approval timeline?

ICH-GCP and Regulatory Considerations

As per EMA and USFDA guidance, sponsor site evaluations must be documented and auditable. Feasibility documentation is considered essential and should be retained within the Trial Master File (TMF).

Alignment with Pharma GMP and GCP guidelines ensures that the selected sites meet international standards for ethical and scientific trial conduct. Refer to resources like StabilityStudies.in for best practices in clinical documentation.

Conclusion

Effective site feasibility questionnaires are vital for strategic site selection and trial success. By tailoring the SFQ to protocol needs and analyzing responses with a structured approach, sponsors can significantly improve recruitment timelines, data quality, and regulatory compliance. A robust feasibility process lays the foundation for a successful clinical trial lifecycle.

Essential Feasibility Metrics for Selecting the Right Clinical Trial Sites

Choosing the right investigational sites is one of the most critical factors influencing the success of a clinical trial. Site feasibility assessments go beyond basic questionnaires—they require evaluating robust metrics that predict a site’s ability to deliver high-quality data, recruit effectively, and meet regulatory standards. This guide explores key feasibility metrics sponsors and CROs should use to select optimal clinical trial sites.

Why Metrics Matter in Site Feasibility

Traditional site selection methods often rely on subjective impressions or past relationships. However, with rising regulatory expectations and protocol complexity, data-driven site selection is now essential. Metrics offer:

• Quantifiable insight into site capabilities
• Better forecasting for patient enrollment
• Improved operational planning
• Reduced risk of non-compliance or delays

Resources such as StabilityStudies.in offer best practices for site documentation and trial integrity.

Top Feasibility Metrics to Evaluate Trial Sites

1. Historical Patient Recruitment Performance

• Number of patients enrolled in previous trials in the same indication
• Speed of enrollment compared to target timelines
• Drop-out and screen failure rates

2. Study Start-Up Timelines

• Average time for Ethics Committee (EC) approval
• Contract finalization time with the sponsor/CRO
• Site initiation visit (SIV) readiness time

3. Regulatory and Audit History

• Number of audits in the last 5 years
• Findings and CAPA responses, if applicable
• Compliance with GMP audit checklist and ICH-GCP standards

4. Therapeutic Area Experience

• Number of trials conducted in the relevant indication
• Specific expertise of principal investigator (PI)
• Availability of trained sub-investigators and coordinators

5. Site Infrastructure Readiness

• Availability of diagnostic tools, labs, and investigational pharmacies
• Functionality of EDC systems and internet bandwidth
• Facilities for IP storage, sample shipment, and patient comfort

Scoring and Ranking Feasibility Metrics

To effectively use metrics, develop a scoring matrix that assigns weights to each criterion based on study priorities. For example:

• Patient Recruitment History: 35%
• Startup Timelines: 25%
• PI and Staff Experience: 15%
• Infrastructure Readiness: 15%
• Audit/Compliance History: 10%

Sites are scored and ranked. Sites below a threshold may be excluded or flagged for risk mitigation.

Digital Tools to Track and Analyze Metrics

• Clinical Trial Management Systems (CTMS)
• Feasibility dashboards within eTMF platforms
• Excel feasibility scoring templates
• CRA report-based feasibility validations

These tools help gather and compare site data across global networks efficiently.

Integrating KPIs into Site Selection SOPs

Use internal Pharma SOP guidelines to standardize feasibility evaluations across studies. SOPs should define:

• What data should be requested
• How metrics are scored and interpreted
• Who is responsible for final site approval

Having consistent feasibility practices improves quality and regulatory inspection readiness.

Regulatory Expectations and Documentation

According to USFDA and EMA, site selection must be justified with documented feasibility assessments. Sponsors must ensure that the process is auditable and that decisions are supported by objective data.

Challenges and Mitigation Strategies

• Incomplete Data from Sites: Encourage sites to provide performance metrics in feasibility questionnaires.
• Overestimated Recruitment: Cross-check against therapeutic benchmarks or past enrollment logs.
• Resource Constraints: Consider central site services or additional monitoring resources.

Conclusion

Feasibility metrics offer a strategic advantage in selecting high-performing clinical trial sites. By using a structured, metrics-driven approach to feasibility, sponsors can reduce risk, optimize enrollment, and ensure quality and compliance throughout the study lifecycle. Effective site selection starts with objective data, not guesswork.

Overcoming Challenges in Global Site Feasibility Assessments

Global site feasibility assessments are essential for selecting suitable clinical trial sites across diverse geographical regions. However, expanding feasibility efforts internationally introduces significant complexities. Sponsors and CROs must navigate regulatory differences, operational hurdles, and cultural nuances while ensuring consistent, quality-driven site selection. This tutorial explores the key challenges in global feasibility and how to mitigate them using standardized processes and informed strategies.

Why Global Feasibility Is More Complex Than Domestic

Unlike single-country feasibility efforts, global feasibility assessments must account for:

• Multiple regulatory environments
• Variations in site infrastructure and SOPs
• Different clinical practices and care standards
• Time zone and language barriers
• Diverse patient populations and recruitment timelines

These factors make data harmonization and feasibility comparisons more difficult, leading to increased trial start-up timelines and variability in study performance.

Major Challenges in Global Site Feasibility Assessments

1. Regulatory Variability Across Countries

• Every region has unique ethics and regulatory approval pathways
• Timelines and documentation requirements vary significantly
• For example, EMA timelines differ widely from CDSCO in India

2. Inconsistent Site Infrastructure and Resources

• Some regions may lack equipment, staff, or digital capabilities
• Site readiness varies by country and sponsor support systems
• Reliability of courier services and sample storage can also impact feasibility

3. Language and Cultural Barriers

• Feasibility forms may need translation and localization
• Misinterpretation of study requirements due to language gaps
• Varying perceptions of clinical research ethics or compensation models

4. Data Privacy and Protection Compliance

• GDPR (EU), HIPAA (USA), and country-specific laws impose different data handling rules
• Compliance requires adapting feasibility forms and data collection methods
• Feasibility systems must ensure encrypted and permissioned access

5. Limited Access to Historical Site Performance

• Global sites may lack a centralized registry for recruitment metrics
• Sponsors must rely on investigator self-reports or use third-party databases
• Site performance may be over- or under-stated without verification

Strategies to Overcome Global Feasibility Challenges

1. Use Standardized Feasibility Templates with Localization

Design standardized templates aligned with protocol needs, but allow localized versions to meet regulatory or language requirements. You can use formats from Pharma SOP templates and adjust based on region.

2. Implement Global CTMS and Dashboards

Use CTMS systems with region-specific fields and dashboards to track site-specific timelines, EC submissions, and investigator qualifications. Integration helps harmonize site comparison across countries.

3. Conduct Remote and On-Site Feasibility Checks

Leverage a hybrid approach of remote feasibility interviews and in-country monitoring visits. Include CRA input from regional teams familiar with local conditions.

4. Train Regional Teams in Feasibility SOPs

Conduct dedicated training for regional staff on global feasibility expectations, sponsor standards, and how to manage cultural sensitivities. Use checklists to ensure consistency across feasibility assessments.

5. Score Sites Using a Weighted, Data-Driven Model

• Assign scores to key feasibility criteria:
• Startup Timelines (30%)
• Infrastructure and Equipment (25%)
• Investigator and Team Experience (20%)
• Past Performance Data (15%)
• Compliance History (10%)
• Rank sites globally for strategic selection

Technology Enablers for Global Feasibility

• REDCap for multilingual feasibility data collection
• Global CTMS systems with EDC and eTMF integrations
• Feasibility tracker templates using Excel or Power BI
• AI-powered feasibility analysis tools

Several tools also offer compliance with regional data protection policies and can be reviewed via portals like StabilityStudies.in.

Documenting and Auditing Global Feasibility Efforts

As per USFDA and other regulators, site feasibility documentation must be audit-ready and preserved in the Trial Master File (TMF). Sponsors should ensure that feasibility outcomes are traceable and decisions justifiable.

Conclusion

Global site feasibility assessments present several operational and regulatory challenges. By standardizing processes, leveraging digital tools, and empowering regional teams, sponsors and CROs can overcome barriers and select sites that are not just eligible—but optimally equipped—for clinical trial success. A structured, transparent feasibility process ensures quality, speed, and global compliance.

Implementing Remote Tools for Virtual Feasibility Evaluations in Clinical Trials

As clinical trials become increasingly global and decentralized, the feasibility evaluation process must also evolve. Traditional on-site visits and in-person feasibility assessments are no longer the only options. Remote tools for virtual feasibility evaluations offer an efficient, scalable alternative for selecting and qualifying investigational sites. This guide explores the essential technologies, benefits, and strategies for executing successful virtual feasibility assessments.

Why Virtual Feasibility Is Gaining Momentum

Virtual feasibility evaluations were initially accelerated by the COVID-19 pandemic, but their benefits have extended far beyond travel restrictions. Sponsors and CROs are increasingly relying on remote solutions to:

• Reduce travel time and cost
• Evaluate more sites in less time
• Ensure timely start-up in global trials
• Digitally document feasibility outcomes for audits

Organizations like StabilityStudies.in emphasize the value of digitized workflows and documentation across the trial lifecycle.

Core Tools for Virtual Feasibility Assessments

1. Electronic Feasibility Questionnaires

• Hosted via platforms like REDCap, Google Forms, or Typeform
• Customizable fields based on protocol-specific requirements
• Multilingual support for global outreach

2. Video Conferencing Platforms

• Zoom, Microsoft Teams, and Webex for real-time PI interviews
• Virtual site tours and discussions with study staff
• Screen sharing to review SOPs, logs, and site infrastructure

3. Clinical Trial Management Systems (CTMS)

• Centralized tracking of feasibility responses and timelines
• Integration with EDC and TMF systems
• Supports real-time status dashboards for sponsors

4. eSignature and Document Sharing Tools

• DocuSign, Adobe Sign for remote document execution
• SharePoint or OneDrive for uploading SOPs, CVs, and licenses
• Ensure compliance with data protection regulations like GDPR and HIPAA

5. Digital Scorecards and Feasibility Algorithms

• Automated scoring of site readiness based on weighted KPIs
• Excel templates, Power BI dashboards, or CTMS-integrated scoring
• Standardized metrics for objective site ranking

Steps for Conducting a Virtual Feasibility Evaluation

1. Prepare a digital feasibility packet including the protocol synopsis, timeline, and expectations.
2. Send electronic questionnaires to shortlisted sites with a defined deadline.
3. Schedule virtual meetings with Principal Investigator and site staff for interviews.
4. Request virtual tours of the pharmacy, lab, IP storage, and patient care areas.
5. Use a standardized checklist to evaluate and score each site.
6. Document and store all outcomes in the sponsor’s CTMS or eTMF.

Benefits of Remote Feasibility Tools

• Scalable site evaluations across multiple countries
• Faster turnaround for start-up decisions
• Reduced overheads for sponsors and CROs
• Minimized carbon footprint through reduced travel

Challenges and Mitigation Strategies

• Limited site technology access: Provide tech support or conduct hybrid assessments.
• Low response rates to digital forms: Use reminders and CRA engagement to boost compliance.
• Data integrity concerns: Store documents in validated CTMS platforms aligned with GMP compliance.

Compliance and Documentation Considerations

According to USFDA and EMA guidelines, feasibility activities—whether virtual or physical—must be documented and retained in the Trial Master File. Electronic feasibility documents must be time-stamped, version-controlled, and audit-ready.

Example: Hybrid Feasibility Approach

Many global sponsors now use hybrid models, where initial assessments are virtual, followed by on-site validation for selected sites. This balances speed and regulatory expectations.

Future of Virtual Feasibility

The future of feasibility is firmly digital. As decentralized trials grow, tools like AI-driven site selection, predictive feasibility scoring, and automated CRA dashboards will further streamline the process. Platforms like Pharma SOP documentation will continue to support digital readiness for all stakeholders involved in trial start-up.

Conclusion

Remote tools are transforming the feasibility landscape in clinical trials. By adopting a structured virtual feasibility strategy using modern tools, sponsors and CROs can reduce delays, improve data quality, and ensure global site readiness. Digital feasibility evaluations are no longer a convenience—they are a competitive advantage in modern clinical research.

Understanding Regulatory Considerations During Feasibility Assessments

Feasibility assessments are a critical step in clinical trial start-up, allowing sponsors and CROs to evaluate whether potential sites can successfully execute a protocol. However, beyond site infrastructure, patient pools, and investigator experience, regulatory compliance is equally vital. Inadequate attention to regulatory requirements during feasibility can lead to delays, rejections, or audit findings. This guide outlines the essential regulatory elements that must be reviewed as part of every feasibility evaluation.

The Role of Regulatory Compliance in Feasibility

Clinical trial regulations set the foundation for ethical conduct, subject protection, and data integrity. Regulatory oversight agencies—such as the USFDA, EMA, and CDSCO—require documented evidence that investigational sites are capable of meeting regulatory standards before approval.

During feasibility, sponsors must verify that a site is not only suitable for operations but also aligns with regional and international guidelines like ICH-GCP. Regulatory gaps at this stage can lead to costly start-up delays or compliance issues post-initiation.

Key Regulatory Checks During Feasibility Assessments

1. Licensing and Accreditation of Site and Investigators

• Principal Investigator (PI) must have valid medical licensure for the country of operation
• Site should be registered with national regulatory authorities (where applicable)
• Verify any historical suspensions, sanctions, or non-compliance records

2. IRB/EC Review Capabilities

• Confirm whether the site has access to a functioning Institutional Review Board or Ethics Committee
• Assess average timelines for initial and continuing review
• Check if the EC complies with national GCP regulations and maintains adequate documentation

3. Informed Consent Process Oversight

• Ensure that informed consent SOPs align with Pharma SOP documentation
• Review the site’s history with vulnerable populations, if applicable
• Determine if translations and local adaptations are supported by EC

4. Regulatory Submissions and Approvals

• Check site familiarity with regulatory submission procedures for CTAs or INDs
• Review documentation timelines from past trials (e.g., CDSCO SUGAM Portal, EMA Clinical Trial Portal)
• Ensure readiness to handle amendments, notifications, and queries during the trial

5. GCP Training and Documentation

• Confirm that all site staff have completed recent GCP training (within 2 years)
• Request training certificates or rosters for documentation
• Evaluate understanding of ICH E6 (R2) and relevant national adaptations

Country-Specific Regulatory Expectations

Each region imposes specific requirements during feasibility. For example:

• India (CDSCO): Sites must be registered with the CDSCO and ECs accredited under NABH or equivalent bodies
• USA (FDA): Requires Form 1572 and Investigator CVs submitted to the IND file
• EU (EMA): Site details must be entered in the CTIS for each trial
• UK (MHRA): Requires pre-approval of site and PI in trial notification

Understanding these differences ensures proper selection and preparedness of sites globally.

Documentation for the Trial Master File (TMF)

As per ICH-GCP and StabilityStudies.in recommendations, feasibility documentation with regulatory components must be maintained in the TMF, including:

• Signed feasibility questionnaires with regulatory declarations
• Copies of licenses, CVs, and GCP training certificates
• EC registration documents
• Feasibility decision-making justifications

Creating a Regulatory Feasibility Checklist

Sponsors should include a dedicated regulatory section in their feasibility checklist covering:

• PI licensing status and experience
• EC operational capability and accreditation
• Historical compliance data (e.g., audit findings, inspection outcomes)
• Submission readiness and GCP compliance

This can be developed into a site scorecard and integrated with the overall site qualification process.

Common Pitfalls and How to Avoid Them

• Assuming EC availability: Always confirm the EC is currently functioning and accepting reviews
• Overlooking licensing renewals: PI or staff may have expired registrations
• Inconsistent GCP records: Ensure centralized verification of training validity
• Lack of audit documentation: Request recent inspection reports, especially if conducted by agencies like TGA or ANVISA

Integrating with Site Feasibility SOPs

Your feasibility SOP should clearly assign responsibilities to regulatory affairs or clinical operations teams for verifying these elements. Regulatory feasibility should be completed before final site approval and revisited during site initiation.

Conclusion

Regulatory considerations are a foundational component of feasibility assessments. They ensure that sites are compliant, inspection-ready, and capable of meeting trial expectations. By embedding regulatory checks early in the feasibility process, sponsors can avoid costly delays and ensure seamless clinical trial execution with full compliance to global standards.